Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery…
FDA Clears Insulet’s Omnipod 5 Automated Insulin Delivery System For Preschool Children
The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ: PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D).
Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $290
Canaccord Genuity analyst Kyle Rose maintains Insulet (NASDAQ:PODD) with a Buy and raises the price target from $250 to $290.
Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance
Insulet Corporation (NASDAQ:PODD) posted a Q2 net loss of $(35) million, or an EPS loss of $(0.50) compared to $(0.37)…
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Omnipod® 5 Automated Insulin Delivery
BTIG Maintains Buy on Insulet, Lowers Price Target to $250
BTIG analyst Marie Thibault maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $310 to $250.
4 Analysts Have This to Say About Insulet
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:
Morgan Stanley Maintains Equal-Weight on Insulet, Lowers Price Target to $244
Morgan Stanley maintains Insulet (NASDAQ:PODD) with a Equal-Weight and lowers the price target from $268 to $244.